

HUMAN ENDOGENOUS RETROVIRUSES AND IMMUNE TOLERANCE IN PREGNANCY

John Even Schjenken

BSc (Biotechnology)

BSc (Biotechnology) (Hons Class 1)



Abstract

The human placenta expresses endogenous retroviral envelope proteins which have been postulated to play an important role in the physiology of pregnancy. Of these, syncytin-1 and syncytin-2 are highly expressed in the syncytiotrophoblast and cytotrophoblast respectively and are thought to be key factors in the regulation of syncytialisation due to their fusogenic properties. In addition to their role in cell fusion, it has also been speculated that syncytin-1 and syncytin-2 may have a role in maternal immune tolerance due to the presence of the highly conserved immunosuppressive domain (ISD) within its sequence. However, no studies are yet to confirm this putative role. Another factor which has been speculated to have a role in maternal immune tolerance is Corticotropin Releasing Hormone (CRH) which has been shown to promote implantation and the maintenance of early pregnancy via the regulation of FasL. Interestingly, both syncytin-1 and FasL have been identified in immunosuppressive placental exosomes. Since CRH stimulates cyclic AMP (cAMP) production and syncytin-1, syncytin-2 and FasL are all stimulated by the cAMP second messenger pathway, it was hypothesised that syncytin-1 and syncytin-2 may be regulated by CRH. Further, it was hypothesised that syncytin-1 may contribute to the modulation of the maternal immune environment during pregnancy. To examine the regulation of syncytin-1 and syncytin-2 by CRH, a combined nucleic acid and protein extraction procedure was developed using column based nucleic acid extraction kits. Using 2D buffer, proteins extracted using this method were shown to have a comparable protein profile to conventionally extracted proteins. This method was then used to examine RNA and protein levels in CRH treated BeWo cells. Following CRH treatment of BeWo cells, a significant upregulation of syncytin-1, syncytin-2 and FasL mRNA was observed. CRH also increased the production of the syncytin-1 precursor in an exosomal fraction. To examine the immunosuppressive properties of syncytin-1, the recombinant ectodomains of human and mouse syncytins were produced and purified using a combination of affinity chromatography and gel filtration. The immunosuppressive properties of the syncytin-1 recombinant ectodomain were then tested using a whole blood culture model stimulated with LPS or PHA.

Syncytin-1 recombinant ectodomain at a concentration of 1 μ M inhibited the production of TNF- α by 50% and CXCL10 by 65% in whole blood cultures following maximal stimulation with LPS. Syncytin-1 recombinant ectodomain also inhibited the production of IFN- γ by 30% in PHA stimulated PBMC. These studies demonstrate for the first time that syncytin-1 has immunosuppressive properties. Further, these studies show that CRH has a role in the stimulation of syncytin-1 and its subsequent sorting into exosomes. Circulating placental exosomes containing syncytin-1 and other immunosuppressive factors including FasL may interact with maternal immune cells to prevent an immune response against the fetal-placental unit. This is a novel mechanism that may contribute to our understanding of how a genetically different fetus can be tolerated by the mother during pregnancy.

Statement of Originality

This thesis contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. I give consent to this copy of my thesis, when deposited in the University library, being made available for loan and photocopying subject to the provisions of the Copyright Act 1968.

John Even Schjenken

July, 2011

Declaration

The work presented in chapter 2 was part of collaborations between John Schjenken and Jorge Tolosa. This work was also presented in the thesis of Jorge Tolosa as an appendice and has been published in the journal *Biotechniques* (1).

<http://dx.doi.org/10.2144/000112594>

A number of figures within this thesis come under the part VB of the *Copyright Act 1968 (the Act)* (see below). These source of these figures are duely referenced in the figure captions.

COMMONWEALTH OF AUSTRALIA

Copyright Regulations 1969

WARNING

This material has been copied and communicated to you by or on behalf of the University of Newcastle pursuant to Part VB of the *Copyright Act 1968 (the Act)*

The material in this communication may be subject to copyright under the Act. Any further copying or communication of this material by you may be the subject of copyright protection under the Act.

Do not remove this notice

Acknowledgements

I would like to take this opportunity to sincerely thank my two supervisors, Professor Roger Smith and Associate Professor Vicki Clifton for giving me the opportunity to be involved with the Mothers and Babies research centre and to present my work at both national and international conferences. You have both been incredibly supportive of me during my time with the group and have always been there whenever I needed help or advice. Most importantly, you both have been patient with my writing. I will forever be thankful for the opportunity you have provided.

I would also like to thank all of the staff and students (past and present) of the Mothers and Babies research centre. I have enjoyed the past 5 years within the group and feel that all of you have contributed in some way, whether it be chatting with me when something didn't work, or giving me scientific support, to the completion of this work. In particular, I would like to thank Dr Kaushik Maiti, Professor Phil Lowry, Ms Julia Smith and Mr Jonathan Tuke who provided me with advice and their expertise with cloning, recombinant protein purification and statistics respectively. I would also like to thank Professor Hungwen Chen and Dr Benoit Barbeau for their generous donation of syncytin antibodies.

Of all of my colleagues I would like to make particular mention of Dr Jorge Tolosa. Jorge, you have taught me so much over the past 5 years, not only in science but also in life. From day one, you took me in and encouraged me to be the best that I can be. This thesis would not have happened without you and I hope that this is just the beginning of our future scientific endeavours.

These studies were carried out with financial support from the Kiriwina Investment Group through the Hunter Medical Research Institute. Travel support was provided by the Endocrine Society of Australia and the Juvenile Diabetes Research Foundation.

I would also like to thank my family and friends for putting up with me for the past 5 years. To my friends, there has always been someone there to take my mind off work when things were not going well and you all have supported me in one way or another. Mum and Dad, you have always supported whatever I have wanted to do and this was no exception. For the past 5 years you have allowed me to continue living at home without board, given me a car to drive and given me every opportunity possible to focus on my work. I couldn't possibly have better parents.

Finally to Ang, when we met I told you that I wasn't far from finishing and that was 4 years ago. While this has taken longer than we would have liked, you were always patient and supported me in my work. You listened to all my complaints when things were not working and put up with some stressful days towards the end. Now we can look forward to the rest of our lives together. I love you very much and am very lucky to have you.

Table of Contents

Chapter 1 - General Introduction	1
1.1 Brief Overview of Placental Morphology	2
1.2 Fetal Immune Evasion Mechanisms	5
1.2.1 Complement System	8
1.2.2 Phosphocholination	11
1.2.3 Programmed Death Ligand 1	12
1.2.4 Major Histocompatibility Complex (MHC) Molecules on the Trophoblast..	14
1.2.5 Tryptophan Catabolism.....	17
1.2.6 Progesterone	19
1.2.7 Th1-Th2 cytokine balance in pregnancy.....	21
1.2.8 Regulatory T Cells	23
1.2.9 Conclusions	24
1.3 Corticotropin Releasing Hormone (CRH) and its regulation of FasL expression	25
1.3.1 CRH and its role in modulating the immune system	28
1.3.2 FasL.....	29
1.3.3 CRH regulation of FasL expression.....	32
1.4 Retroviruses	33
1.4.1 A Brief History in Retrovirology	34
1.4.2 Retroviral Life Cycle.....	35
1.4.2.1 Endogenous Retroviruses (ERVs)	35
1.5 The Human Placenta and ERVs.....	36
1.5.1 Syncytin-1 (HERV-W).....	38
1.5.2 Syncytin-2 (HERV-FRD).....	40
1.5.3 Syncytin-A and Syncytin-B	41
1.5.4 Regulation of Placental Syncytin Expression	42
1.6 Retroviruses and Immunosuppression	43
1.6.1 CKS-17.....	44
1.6.1.1 Respiratory Burst of Human Monocytes.....	45
1.6.1.2 Human Natural Killer (NK) Cell Activity	45
1.6.1.3 Monocyte-Mediated Tumour Cell Killing	46
1.6.1.4 IgG Production	46
1.6.1.5 In Vitro Production of IFN- γ and TNF- α by Human Peripheral Blood Mononuclear Cells (PBMCs).....	47
1.6.1.6 Interleukin-1 (IL-1) Mediated Responses by Interfering with Signal Transduction Through a Protein Kinase C Pathway	47
1.6.1.7 Cell-Mediated Immunity (DTH) Reactions In Vivo in Mice	47
1.6.1.8 Lipopolysaccharide (Endotoxin)-Induced Mortality of Mice	48
1.6.1.9 Murine Cytotoxic T Lymphocyte Activity	48
1.6.2 In Vivo Studies of Retroviral Envelope Protein Mediated Immune Suppression	48
1.6.3 Immunosuppressive Role of Placental ERV Envelope Proteins.....	51

1.7 The Trojan Exosome Hypothesis and Immunosuppressive Placental Exosomes	55
1.8 Thesis Hypothesis	57
1.8.1 Thesis Aims.....	57

Chapter 2 - A Column Based Method to Simultaneously

Extract DNA, RNA and Protein from the Same Sample.....58

2.1 Abstract	59
2.2 Introduction	60
2.3 Methods.....	62
2.3.1 Tissue Preparation.....	62
2.3.2 Spin Column Extractions	62
2.3.2.1 Purification of Total RNA and Protein using the RNeasy Mini Kit (QIAGEN).....	62
2.3.2.2 Purification of DNA, RNA and Protein using the DNA/RNA kit (QIAGEN).....	63
2.3.3 Protein extraction	63
2.3.3.1 Conventional	63
2.3.3.2 Column based proteins.....	64
2.3.4 Protein Determination	64
2.3.4.1 BCA kit	64
2.3.4.2 2D Quant kit.....	64
2.3.5 Protein analysis	65
2.3.5.1 SDS-PAGE.....	65
2.3.5.2 Silver stain.....	65
2.3.5.3 Western Blotting	65
2.3.5.4 2D Gel Electrophoresis	66
2.4 Results.....	67
2.4.1 Nucleic acid quantification and quality	67
2.4.2 One-dimensional protein analysis.....	67
2.4.3 Comparative analysis of protein profiles obtained using the RNeasy column, DNA/RNA column and conventional 2D protein extraction buffer	70
2.4.4 Western Blotting	72
2.4.5 2-Dimensional analysis of proteins extracted using conventional and column based methods	73
2.5 Discussion	76

Chapter 3 - A new mechanism for CRH induced

immunosuppression during pregnancy80

3.1 Abstract	81
3.2 Introduction	82
3.3 Materials and Methods.....	86
3.3.1 Cell culture	86
3.3.2 RNA and protein extraction	86
3.3.2.1 RNA sample purification	87

3.3.2.2 Reverse Transcription	87
3.3.2.3 Real-Time PCR	87
3.3.4 Protein determination – 2D quant kit	89
3.3.5 Exosome extraction	89
3.3.6 SDS-PAGE	90
3.3.6.1 Silver stain	90
3.3.6.2 Western Blotting	90
3.3.7 Electron microscopy	91
3.3.8 Statistics	91
3.4 Results	93
3.4.1 Syncytin-1, Syncytin-2 and FasL Expression Profile Following CRH Treatment	93
3.4.2 Exosomes increase in BeWo cell media following CRH treatment	96
3.5 Discussion	98

Chapter 4 - The Generation and Characterisation of

Recombinant Syncytin Ectodomain Proteins103

4.1 Abstract	104
4.2 Introduction	105
4.3 Methods	108
4.3.1 cDNA Preparation	108
4.3.1.1 RNA Extraction	108
4.3.1.2 RNase-Free DNase Treatment	108
4.3.1.3 RNA Analysis	108
4.3.1.4 Reverse Transcription	109
4.3.2 Polymerase Chain Reaction (PCR) Amplification of Syncytin Recombinant Ectodomain Sequences	109
4.3.2.1 Primer Design	109
4.3.2.2 PCR	111
4.3.2.3 Agarose Gel Electrophoresis	111
4.3.2.4 DNA Fragment Purification	111
4.3.3 Cloning of Syncytin Recombinant Ectodomains	112
4.3.3.1 Restriction Enzyme Digestion	112
4.3.3.2 Ligation Reaction (pET 28-b)	112
4.3.3.3 Competent Cell Preparation	113
4.3.3.4 pET 28-b Transformation	113
4.3.3.5 Plasmid Mini-Prep	114
4.3.3.6 Sequencing	114
4.3.4 Syncytin Recombinant Ectodomain Protein Induction	115
4.3.4.1 BL21-CodonPlus® Competent Cell Transformation	115
4.3.4.2 Optimisation of Recombinant Ectodomain Protein Expression	115
4.3.4.3 Recombinant Ectodomain Protein Induction Protocol (Syncytin-1, 2 and B)	116
4.3.4.4 Recombinant Ectodomain Protein Induction Protocol (Syncytin-A) ...	116
4.3.5 Purification of Syncytin Recombinant Ectodomain Proteins	117

4.3.5.1 Hitrap Immobilised Metal Affinity Chromatography (Hitrap IMAC) ..	117
4.3.5.2 Gel Filtration – Superdex 75 10/300GL	117
4.3.6 Confirmation of Syncytin Recombinant Ectodomain Protein Expression...	118
4.3.6.1 SDS-PAGE	118
4.3.6.2 Coomassie Gel Staining	118
4.3.6.3 Silver Stain	119
4.3.6.4 Sypro Ruby	119
4.3.6.5 Western Blotting	119
4.3.7 Protein Sequencing	120
4.3.7.1 Gel-Plug Preparation for LCMS Sequencing	120
4.3.7.2 In Solution Preparation for LCMS Sequencing	121
4.3.7.3 LCMS Sequencing	121
4.4 Results	123
4.4.1 Cloning of Syncytin Recombinant Ectodomains	123
4.4.2 Optimisation and Characterisation of Syncytin Recombinant Ectodomains Proteins from Total Bacterial Lysates	126
4.4.3 Purification and Characterisation of Syncytin Recombinant Ectodomain Proteins	128
4.5 Discussion	138

Chapter 5 - Immunosuppressive Properties of the Placental

Endogenous Retroviral Envelope Protein Syncytin-1.....143

5.1 Abstract	144
5.2 Introduction	145
5.3 Methods	148
5.3.1 Recombinant Proteins	148
5.3.1.1 Production and Purification	148
5.3.1.2 Quantification of Recombinant Protein Concentration	148
5.3.1.3 Endotoxin Calculation	149
5.3.2 Blood Collection	149
5.3.2.1 Whole Blood Culture	149
5.3.2.2 Peripheral Blood Mononuclear Cell (PBMC) Culture	150
5.3.3 Cell Viability	151
5.3.3.1 Lactate Dehydrogenase (LDH) Activity Assay	151
5.3.4 Cytokine Production	151
5.3.4.1 ELISA	151
5.3.4.2 Bead Array	152
5.3.5 Statistics	153
5.4 Results	154
5.4.1 TNF- α Response to LPS stimulation	154
5.4.2 Characterisation of the Immunological Properties of Syncytin-1 Recombinant Ectodomain	155
5.4.2.1 Immunosuppressive Properties of Syncytin-1 Recombinant Ectodomain	156
5.5 Discussion	164

Chapter 6 - General Discussion	170
6,1 General Discussion.....	171
6.1.1 Preeclampsia	182
6.1.2 Cancer	182
6.1.3 Transplantation.....	183
6.1.4 Future studies	184
6.2 Final conclusions.....	186
Chapter 7 – References.....	187
7.1 References	188
Appendix 1	213
A.1 Buffers	214

Table of Figures

Figure 1.1. Schematic representation of the three main types of placentation, showing the relationship between the fetal trophoblast cells and maternal blood. a) <i>Epitheliochorial</i> . Trophoblast cells of the placenta are in direct apposition with the surface epithelial cells of the uterus but there is no trophoblast-cell invasion beyond this layer. b) <i>Endotheliochorial</i> . The uterine epithelium is breached and trophoblast cells are in direct contact with endothelial cells of maternal uterine blood vessels. c) <i>Haemochorial</i> . Maternal uterine blood vessels are infiltrated by trophoblast cells causing rupture and release of blood into the intervillous space. The outer layer of the chorionic villi (syncytiotrophoblast) is now bathed in blood. Adapted from (4).	3
Figure 1.2. Cytotrophoblast differentiation. Cytotrophoblasts grow into the maternal decidua from a basement membrane and differentiate into several cell types. Some form the anchoring villus that attaches the placenta to the lining of the uterus, others invade through decidual tissue until they reach the maternal spiral arteries where they transform into an endothelial phenotype, and another group fuse to form the syncytiotrophoblast layer that lines the villus space (6).	4
Figure 1.3. Schematic diagram of the three complement activation pathways. Complement can be activated by the classical, mannose binding lectin or alternative pathways. These pathways cause the cleavage of C3 into C3a or C3b ultimately resulting in inflammation, tissue injury or cell lysis activation (adapted from (23)).	9
Figure 1.4. Apoptosis signalling through Fas/FasL interactions. The binding of FasL to Fas induces the recruitment of the FADD and caspases to the receptor complex to form the DISC. The DISC causes activation of caspase-3 through two pathways (death substrate or mitochondrial) which ultimately result in cell death by apoptosis. Adapted from (140)).	31
Figure 1.5. Genomic structure of a retrovirus. Retroviruses consist of two long terminal repeats at the 5' and 3' ends and three genes, gag, pol, and env. Adapted from (147).	33
Figure 1.6 Envelope protein structure. The envelope protein of retroviruses is divided into 2 subunits. The surface subunit (SU) is involved in receptor signalling while the transmembrane subunit is involved in anchoring the envelope to the membrane, fusion of cells and putative immunosuppression (adapted from (168)).	39
Figure 1.7 Tumour cell growth in mice expressing fragments of the envelope protein of MMuLV. Induction of tumour growth by retroviral envelope expression only requires the TM subunit as demonstrated by the figure on the right. Mice were injected with tumour cells either expressing the envelope or transmembrane subunit (A) or a control (B). The percentage of animals with tumours is represented by grey bars while the black bars represent mean tumour area (mm ²) (210).	49
Figure 1.8. The effects of retroviral-mediated immune suppression on distant sites of the body. Transmembrane subunit expression does not affect the rejection of non-transduced cells at a distant site. Immune regulation was observed in tumour cells expressing the transmembrane subunit (A) while control tumour cells were rejected by the immune system (B) (210).	50

- Figure 1.9. Immunosuppressive properties regulated by the HERV-H envelope protein. Tumour cells expressing the HERV-H envelope protein and control tumour cells were injected subcutaneously into mice. The percentage of animals with the tumour was examined to determine the immunosuppressive properties. MCA205env-H represents tumour cells containing the HERV-H envelope while MCA205none are control cells. Black bars represent the percentage of animals with the tumour while grey bars represent the mean tumour area (mm²) (211). 51
- Figure 1.10. Immunosuppressive properties of placental syncytins. Tumour cells expressing syncytin-1 and syncytin-2 and control tumour cells were injected subcutaneously into mice. The percentage of animals with the tumour was examined to determine the immunosuppressive properties. Grey bars represent the percentage of animals with the tumour while black bars represent the mean tumour area (mm²) (214). 53
- Figure 1.11. Representative experiment showing the effect of Syncytin-1 ISD peptide on TNF- α production by human blood cells after stimulation with different concentrations of LPS. A 30% inhibition in TNF- α production was observed with 30uM Syncytin-1ISD when blood was stimulated with 10ug or 100ug of LPS. No effect was observed with the Syncytin-1ISD Reverse sequence at any concentration. A logarithmic curve fitting is shown. Bar graphs show mean $\pm$ SD. Results are representative of three experiments (191). 55
- Figure 2.1. Representative silver stain and densitometry analysis of placental proteins extracted using conventional methods and the RNeasy kit (Qiagen). A) SDS-PAGE silver stained placental proteins: Lanes 1-3 Proteins conventionally extracted using RIPA buffer; Lanes 4-6 Proteins conventionally extracted using 2D buffer; Lanes 7-9 Proteins extracted using RNeasy column and resuspended in RIPA buffer; Lanes 10-12 Proteins extracted using RNeasy column and resuspended in 2D buffer. Molecular weight standard (Mark12 Invitrogen). B) Representative silver stain of pooled placental proteins initially resuspended in RIPA buffer and the remaining pellet resuspended in 2D buffer. C) Densitometrical analysis of pooled placental proteins extracted using conventional methods and the RNeasy kit (Qiagen). Fugi-film software was used to analyze the density of each band and a densitometrical plot was obtained. Blue = Proteins conventionally extracted using RIPA buffer, Green = Proteins conventionally extracted using 2D buffer, Aqua = Proteins extracted using the RNeasy column and resuspended in RIPA buffer, Pink = Remaining pellet from proteins extracted with RNeasy using RIPA, resuspended in 2D buffer, Salmon = Combined proteins extracted with RNeasy using RIPA and 2D buffer. 69
- Figure 2.2. Representative silver stain and densitometry analysis of placental proteins conventionally extracted using 2D buffer or RNeasy column and DNA/RNA column and resuspended in 2D buffer. A) Representative silver stain of pooled placental proteins conventionally extracted using 2D buffer and column based methods. Molecular weight standard (Mark12). Lane 1 Pooled proteins conventionally extracted using 2D buffer; Lane 2, Pooled proteins extracted using the DNA/RNA column and resuspended in 2D buffer; Lane 3 Pooled proteins extracted using the RNeasy column and resuspended in 2D buffer. B) Densitometric analysis of pooled placental proteins using Fugifilm densitometrical analysis software. Blue = Pooled proteins conventionally extracted with 2D buffer, Green = Pooled proteins extracted

- with DNA/RNA columns and resuspended in 2D buffer, Aqua = Pooled proteins extracted with the RNeasy columns and resuspended in 2D buffer. 71
- Figure 2.3. Western blot of placental proteins extracted using the conventional method and the column based methods. Proteins were checked for their compatibility with Western Blotting using an antibody against alpha actin (42kDa). Lane 1 Proteins conventionally extracted using 2D buffer, Lane 2 & 3 Proteins extracted using the DNA/RNA columns and resuspended in 2D buffer, Lane 4 & 5 Proteins extracted using the RNeasy column and resuspended in 2D buffer. 72
- Figure 2.4. 2D gels detailing conventional 2D buffer extraction, RNeasy and DNA/RNA proteins resuspended in 2D buffer. Sypro Ruby was used to detect the protein bands. A) Proteins conventionally extracted using 2D buffer B) Proteins extracted using DNA/RNA columns and resuspended in 2D buffer C) Proteins extracted using RNeasy columns and resuspended in 2D buffer. Whole gels were then separated into regions for better analysis (D to F). Proteins were extracted using the conventional (top), DNA/RNA (middle) and RNeasy (bottom) (D to F). Dashed boxes are used to define regions where similarities can be observed. Other boxes and circles are used to define regions where differences can be observed: D) 66-200 kDa, E) 31-61 kDa, and F) 6-31 kDa. 75
- Figure 3.1. RT-PCR analysis of syncytin-1 (A), syncytin-2 (B) and FasL (C) in BeWo cells treated with different concentrations of CRH. 18srRNA was used as an internal control and the values were calculated using the delta C(t) method. Expression levels were normalised by dividing treated sample readings by the equivalent vehicle. * indicates $p < 0.05$ when compared to the no treatment control (0). P values; syncytin-1; 10($p = 0.028$), 25($p = 0.048$), 50($p < 0.001$), 200($p = 0.024$); syncytin-2; 50($p < 0.001$); FasL; 25($p = 0.013$), 50($p < 0.001$). $n = 3$ 94
- Figure 3.2. Densitometric analysis of syncytin-1 (A), syncytin-2 (B) and FasL (C) protein expression determined by western blot in BeWo cells treated with 50nM CRH. Actin was used as the internal standard and the values were calculated using Fujifilm densitometry software. Expression levels were normalised by dividing specific protein values (syncytin-1, syncytin-2 or FasL) by actin and graphed. No significant differences were detected between any of the treatment groups of syncytin-1 (A), syncytin-2 (B) and FasL (C). Molecular weight standard; Magic mark (Invitrogen), NT; No treatment. 50V; 50nm CRH vehicle. 50; 50nm CRH. 95
- Figure 3.3. Transmission electron micrographs of exosomes collected from BeWo cells using differential centrifugation followed by sucrose cushion. Exosomes are membrane nanovesicles approximately 100nm in diameter with a density ranged from 1.120 to 1.160 g/cm³. Inset – close up image of BeWo exosome. 96
- Figure 3.4 Representative silver stain and syncytin-1 western blot of exosomal proteins extracted from CRH treated BeWo cells. A) Representative silver stain of CRH treated exosomal protein. B) Representative western blot of syncytin-1 protein expression in exosomes produced by BeWo cells after CRH stimulation. In these experiments, an equal number of BeWo cells were treated by CRH. The loading of these gels was therefore controlled by the number of BeWo cells treated with CRH. Observe the dose dependent increase in syncytin-1 protein in exosomes, reaching a significant peak at 50nM CRH treatment (lane 6). Results are representative of 3 experiments. M - Molecular Weight standard; Mark12 (Invitrogen); 1 – Vehicle for

- 10nM CRH; 2 – 10nM CRH; 3 – Vehicle for 25nM CRH; 4 – 25nM CRH; 5 – Vehicle for 50nM CRH; 6 – 50nM CRH; 7 – Vehicle for 100nM CRH; 8 – 100nM CRH; 9 – Vehicle for 200nM CRH; 10 – 200nM CRH. 97
- Figure 4.1. Syncytin recombinant ectodomain amplification. Syncytin ectodomain gene sequences were amplified by PCR using gene specific primers and resolved using agarose gel electrophoresis. Amplicons were excised and purified for use in molecular cloning. DNA ladder = 100bp ladder (Invitrogen), ‘-’ = reverse transcription negative control, ‘+’ = Amplified ectodomain sequence. A) Syncytin-1 (189bp), B) Syncytin-2 (189bp), C) Syncytin-A (198bp), D) Syncytin-B (198bp). ... 123
- Figure 4.2. Restriction enzyme digestion of syncytin ectodomain gene sequences and the pET 28-b plasmid. Agarose gel electrophoresis was used to resolve digested plasmid or insert prior to purification using Wizard SV gel PCR purification kit (Promega). A) Ectodomain inserts were digested with 1Unit of BspH1 and 1Unit of Xho1 at 37°C for 16hours. Ladder; 100bp ladder (Invitrogen). The example shown in A) is digested syncytin-1 ectodomain B) 3µg pET-28b was digested with 2.5 Units NcoI and 10 Units XhoI at 37°C for 4 hours. Ladder; 1kb ladder (Invitrogen). 124
- Figure 4.3. Syncytin ectodomain pET28-b clones. Syncytin ectodomain gene sequences cloned into pET 28-b were amplified by PCR using gene-specific primers and resolved using agarose gel electrophoresis. Correct sized clones (depicted by an amplicon of similar intensity to the positive control – placental tissue) were purified using the Gen-Elute Plasmid mini-prep kit (Sigma) and sent to AGRF for DNA sequencing. Ladder = 100bp ladder (Invitrogen), ‘+’ = positive control, ‘-’ = negative control, ‘#1-16’ = syncytin ectodomain pET 28-b plasmid number. A) syncytin-1 (189bp), B) syncytin-2 (189bp), C) syncytin-A (198bp), D) syncytin-B (198bp). 125
- Figure 4.4. Optimisation of syncytin recombinant ectodomain protein induction. Syncytin recombinant ectodomain pET 28-b clones were grown in BL21–Codon Plus® competent cells and induced with 1mM IPTG for 2 hours. Total bacterial proteins were run on a 12% Bis-Tris SDS-PAGE gel with MES running buffer and the protein profile was determined by staining with Coomassie brilliant blue gel stain. Ladder = Mark12 (Invitrogen), UI = uninduced sample, I = induced sample. A) syncytin-1, B) syncytin-2, C) syncytin-A, D) syncytin-B. Arrows indicate the induced recombinant protein. 126
- Figure 4.5. Western Blotting analysis of syncytin recombinant ectodomains using His-tag antibody. Syncytin recombinant ectodomain pET 28-b plasmids were grown in BL21 – Codon Plus® competent cells and induced with 1mM IPTG for 2 hours. Total bacterial proteins were run on a 12% Bis-Tris SDS-PAGE gel with MES running buffer and transferred to nitrocellulose membranes. Membranes were probed with anti-His-tag antibody (1:1000 dilution) to confirm the specificity of the protein to syncytin recombinant pET 28-b plasmid. Ladder = Magic mark (Invitrogen), - = uninduced sample, + = induced sample. A) Syncytin-1, B) Syncytin-2, C) Syncytin-A, D) Syncytin-B. Arrows indicate the induced recombinant proteins. 128
- Figure 4.6. Syncytin-A is expressed in inclusion bodies. Syncytin-A recombinant ectodomain plasmids were grown in BL21 – Codon Plus® competent cells and induced with 1mM IPTG for 2 hours. Total bacterial proteins were separated into

- soluble and insoluble inclusion body fractions and were run on a 12% Bis-Tris SDS-PAGE gel with MES running buffer. The protein profile was determined by staining the gel with Coomassie brilliant blue gel stain. Ladder = Mark12 (Invitrogen), 1 = Insoluble inclusion body fraction, 2 = Soluble protein fraction. An arrow indicates the induced recombinant proteins which appear only in the insoluble inclusion body fraction. 129
- Figure 4.7. Chromatogram of Ovalbumin and Ribonuclease A standards run using Superdex 75 10/300 GL column (GE healthcare) on ÄKTA™ FPLC™ (GE healthcare). A) GE healthcare elution profile for 500µl standard (BSA (1) – 67kDa – 8mg/ml, Ovalbumin (2) – 43kDa – 2.5mg/ml, Ribonuclease A (3) – 13.7kDa – 5mg/ml, Apoprotinin (4) – 6.5kDa – 2mg/ml, Vitamin B12 (5) – 1.355kDa – 1mg/ml) after sample was run on Superdex 75 10/300 GL in 50mM phosphate buffer, 150mM NaCl, pH7 at 0.4ml/min. B) 500µl of 2.5mg/ml Ovalbumin (43kDa) and 5mg/ml Ribonuclease A (13.7kDa) was run through Superdex 75 10/300 GL in 25mM HEPES, 150mM NaCl, pH 8.5 at 0.15ml/min. Ovalbumin eluted in fraction 10l while Ribonuclease A eluted at 14ml. 130
- Figure 4.8. Syncytin-1 ectodomain purification. Syncytin-1 ectodomain was induced in 1mM IPTG and soluble protein was isolated using centrifugation methods. Syncytin-1 ectodomain was then purified by affinity chromatography using Hitrap IMAC HP methods (A, B). Complete purification was achieved through two runs through the Superdex 75 10/300 gel filtration column in 25mM HEPES, 150mM NaCl pH7.4 (C-F). A, C and E show representative graph/chromatograms of syncytin-1 ectodomain following Hitrap IMAC HP methods (A) or Superdex 75 10/300GL purification (C and E – blue line). B, D and F show a representative Coomassie stained SDS-PAGE gel of syncytin-1 ectodomain eluted from either Hitrap IMAC (B) or Superdex 75 10/300 GL (D or F) columns. Protein ladder = Mark12 (Invitrogen); Before (B) = Sample before application to Hitrap column; After = Sample after application to Hitrap column; #1-20 = Sample elution from column. 132
- Figure 4.9. Syncytin-2 ectodomain purification. Syncytin-2 ectodomain was induced in 1mM IPTG and soluble protein was isolated using centrifugation methods. Syncytin-2 ectodomain was then purified by affinity chromatography using Hitrap IMAC HP methods (A, B). Complete purification was achieved through two runs through the Superdex 75 10/300 gel filtration column in 25mM HEPES, 150mM NaCl pH7.4 (C-F). A, C and E show a representative graph/chromatogram of syncytin-2 ectodomain following Hitrap IMAC HP methods (A) or Superdex 75 10/300GL purification (C and E – blue line). B, D and F show a representative Coomassie stained SDS-PAGE gel of syncytin-2 ectodomain eluted from either Hitrap IMAC (B) or Superdex 75 10/300 GL (D or F) columns. Protein ladder = Mark12 (Invitrogen); Before (B) = Sample before application to Hitrap column; After = Sample after application to Hitrap column; #1-17 = Sample elution from column. 133
- Figure 4.10. Syncytin-A ectodomain purification. Syncytin-A ectodomain was induced in 1mM IPTG and the insoluble inclusion body fraction was isolated using centrifugation methods. Syncytin-A ectodomain was initially purified by affinity chromatography using Hitrap IMAC HP methods (A, B). Complete purification was achieved through two runs through the Superdex 75 10/300 gel filtration column in 25mM HEPES, 150mM NaCl pH7.4 (C-F). A, C and E show a representative

- graph/chromatogram of syncytin-A ectodomain following Hitrap IMAC HP methods (A) or Superdex 75 10/300GL purification (C and E – blue line). B, D and F show a representative Coomassie stained SDS-PAGE gel of syncytin-A ectodomain eluted from either Hitrap IMAC (B) or Superdex 75 10/300 GL (D or F) columns. Protein ladder = Mark12 (Invitrogen); Before (B) = Sample before application to Hitrap column; After = Sample after application to Hitrap column; #1-19 = Sample elution from column. 134
- Figure 4.11. Syncytin-B ectodomain purification. Syncytin-B ectodomain was induced in 1mM IPTG and soluble bacterial protein was isolated using centrifugation methods. Syncytin-B ectodomain was then purified by affinity chromatography using Hitrap IMAC HP methods (A, B). Complete purification was achieved through two runs through the Superdex 75 10/300 gel filtration column in 25mM HEPES, 150mM NaCl pH7.4 (C-F). A, C and E show a representative graph/chromatogram of syncytin-B ectodomain following Hitrap IMAC HP methods (A) or Superdex 75 10/300GL purification (C and E – blue line). B, D and F show a representative Coomassie stained SDS-PAGE gel of syncytin-B ectodomain eluted from either Hitrap IMAC (B) or Superdex 75 10/300 GL (D or F) columns. Protein ladder = Mark12 (Invitrogen); Before (B) = Sample before application to Hitrap column; After = Sample after application to Hitrap column; #1-15 = Sample elution from column. 135
- Figure 4.12. Representative Western blot of purified syncytin recombinant ectodomains. Representative Western Blot of purified recombinant ectodomains of human syncytin-1 and syncytin-2 (A-B and C-D); and mouse syncytin-A and syncytin-B (E-F and G-H) generated in *E. coli*. 2µg of purified protein was used. Layout of membranes are as follows; A) and B) 1 - Magic mark (Invitrogen), 2 – syncytin-1 ectodomain fraction 10, 3 – syncytin-1 ectodomain fraction 12; C) and D) 1 - Magic mark (Invitrogen), 2 – syncytin-2 ectodomain fraction 10, 3 – syncytin-2 ectodomain fraction 12; E) and F) 1 - Magic mark (Invitrogen), 2 – syncytin-A ectodomain fraction 10, 3 – syncytin-A ectodomain fraction 12; G and H 1 - Magic mark (Invitrogen), 2 – syncytin-B ectodomain fraction 10, 3 – syncytin-B ectodomain fraction 12. A), C), E) and G) syncytin AbL Pre-Immune Sera (1:1000), B), D), F) and H) syncytin AbL Immune Sera (1:1000). 137
- Figure 5.1. TNF-α secretion in whole blood cells in response to different concentrations of LPS. LPS dose response experiment showing stimulation of TNF-α production by whole human blood.. Whole human blood was diluted in 25mM HEPES, 150mM NaCl, pH7.4 to give a final concentration of 500 000 cells/well and incubated for 24 hours at 37°C with different concentrations of LPS. The amount of TNF-α secreted by culture media alone was at the detection limit of our assay. The maximum stimulating dose of LPS was 10000ng/ml (10µg/ml). The data are from 4 independent experiments and the error bars refer to standard error. 154
- Figure 5.2. Syncytin-1 recombinant ectodomain elution profile. A) SDS-PAGE of purified syncytin-1 ectodomain. B) FPLC chromatogram of purified syncytin-1 ectodomain. Syncytin-1 recombinant ectodomain was produced in *E.coli* as a soluble His-tagged protein and purified using affinity chromatography (Hitrap) and gel filtration chromatography (Superdex 75 10/300GL). The recombinant protein eluted

as two peaks; a smaller 10ml peak (Fraction 10) and a 12ml peak (Fraction 12) which corresponded to the majority of protein in the sample.	155
Figure 5.3. Inhibition of TNF- α production using syncytin-1 recombinant protein from fraction 12. No decrease in TNF- α production from whole blood was observed following maximum stimulating doses of LPS (10ug/ml) and treatment with different concentrations of syncytin-1 recombinant protein from fraction 12. Data are the mean from 4 individual experiments and the error bars refer to standard error. ...	156
Figure 5.4. Inhibition of IFN-gamma production in PHA stimulated whole blood using syncytin-1 recombinant protein. A 30% inhibition of IFN-gamma compared to the vehicle control was observed using 1 μ M syncytin-1 recombinant protein following treatment of PBMC with PHA. * - $P < 0.05$ compared to Blood + CM + PHA (2 μ g). The data are from 3 experiments and the error bars refer to standard error.	157
Figure 5.5. Cytotoxicity of whole blood cells stimulated with LPS and treated with syncytin-1 recombinant protein from fraction 12. Cytotoxicity of whole human blood cells treated with maximum stimulating doses of LPS and syncytin-1 recombinant protein was measured by the LDH assay. No significant difference in LDH was observed between treatments and vehicles at any concentration of syncytin-1 recombinant protein. Data are the mean from 3 individual experiments and the error bars refer to standard error.	158
Figure 5.6. Inhibition of TNF-alpha production using syncytin-1 recombinant protein from fraction 10. A dose dependent decrease in TNF-alpha production from whole blood was observed following maximum stimulating doses of LPS (10ug/ml) and treatment with different concentrations of syncytin-1 recombinant protein fraction 10. An inhibition of 50% TNF-alpha compared to the vehicle control was observed using 1uM syncytin-1 recombinant protein. Data are the mean from 5 individual experiments and the error bars refer to standard error. ** - $P < 0.01$ compared to the no treatment control.	159
Figure 5.7. Cytotoxicity of whole blood cells stimulated with LPS and treated with syncytin-1 recombinant protein from fraction 10. Cytotoxicity of whole human blood cells treated with maximum stimulating doses of LPS and syncytin-1 recombinant protein was measured by the LDH assay. No significant difference in LDH was observed between treatments and vehicles at any concentration of syncytin-1 recombinant protein. Data are the mean from 3 individual experiments and the error bars refer to standard error.	160
Figure 5.8. Inhibition of TNF-alpha production in whole blood stimulated with LPS using syncytin-1 recombinant protein from fraction 10-12. A dose dependent decrease in TNF-alpha production was observed following maximum stimulating doses of LPS (10ug/ml) and treatment with different concentrations of syncytin-1 recombinant protein. An inhibition of 45% TNF-alpha compared to the vehicle control was observed using 1uM syncytin-1 recombinant protein. Data are the mean from 5 individual experiments and the error bars refer to standard error. ** - $p < 0.01$ compared to the no treatment control.	161
Figure 5.9. Cytotoxicity of whole blood cells stimulated with LPS and treated with syncytin-1 recombinant protein from fraction 10-12. Cytotoxicity of whole human blood cells treated with maximum stimulating doses of LPS and syncytin-1 recombinant protein was measured by the LDH assay. No significant difference in	

<i>LDH was observed between treatments and vehicles at any concentration of syncytin-1 recombinant protein. Data are the mean from 3 individual experiments and the error bars refer to standard error.</i>	162
<i>Figure 5.10. Inhibition of CXCL10 production in LPS stimulated whole blood using syncytin-1 recombinant protein fraction 10. An inhibition of 65% CXCL10 compared to the vehicle control was observed using 1uM syncytin-1 recombinant protein following treatment of whole blood with maximal stimulating doses of LPS (10ug/ml). Data are the mean of 5 individual experiments and the error bars refer to standard error. ** - $p < 0.01$ compared to Blood + CM + LPS.</i>	163
<i>Figure 6.1. Schematic of the possible role of syncytin-2 during pregnancy. Recent studies have suggested that syncytin-2 has immunosuppressive properties, however, the authors have not attempted to put this immunosuppressive role in context considering that syncytin-2 is expressed in the cytotrophoblast and is not in direct contact with the maternal circulation. This thesis proposes that the increasing CRH levels during gestation stimulate the production of syncytin-2 in the cytotrophoblast which interacts with the syncytin-2 receptor on the syncytiotrophoblast resulting in cytotrophoblast cell fusion. STL = Syncytiotrophoblast layer, CT = Cytotrophoblast, S2R = Syncytin-2 receptor, CTDC = Cytotrophoblast Daughter Cell, CTSC = Cytotrophoblast Stem Cell.</i>	175
<i>Figure 6.2. Schematic of the possible immunosuppressive role of syncytin-1 throughout gestation. During pregnancy, the semi-allogenic fetus expresses antigens derived from both the mother and the father without immunological rejection. This thesis proposes that the increasing CRH levels during gestation stimulate the production of syncytin-1 and FasL which are sorted into exosomes along with a number of other immunosuppressive factors and released into the maternal circulation impairing the ability of circulating immune cells to mount an immune response against the semi-allograft fetus resulting in maternal immune tolerance. STL = Syncytiotrophoblast layer, CTL = Cytotrophoblast layer.</i>	181

Table of Tables

Table 1.1. The fusogenic potential of the 18 coding <i>env</i> genes in the human genome. <i>Cell-fusion assays were performed using the following cell-types: NIH3T3, CHO, G355-5, Cos-7, TE671, 293T, and HeLa. ‘-’ negative result in all cell types, ‘+’ positive result in at least one cell type (108).</i>	38
Table 1.2. Sequence alignment of the ISD of placental syncytins compared with CKS-17. <i>The sequence of the ISD of placental syncytins was compared to CKS-17. The percent of homology (black) is presented along with the percent of similarity (red). All placental syncytins had some homology with the CKS-17 peptide.</i>	52
Table 3.1. Primer Sequences for RT-PCR	88
Table 4.1. PCR and sequencing primers for syncytin ectodomains. <i>PCR primers are based upon those used in Mangeney et. al., 2007 (213). T7 promoter primer was used as the sequencing primer Syncytin-1 and syncytin-2 primers are direct copies of Mangeney et al., 2007 primers while syncytin-A and syncytin-B were altered slightly to include NcoI and XhoI restriction enzyme sites. Bold = Spacer, Italics = Enzyme cut site, Normal = Sequence.</i>	110
Table 4.2. Antibodies used for Western Blotting. <i>The primary antibody is detailed in the left column and the corresponding secondary antibody is detailed in the right column.</i>	120

Abbreviations

CHAPS -	3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate
ACTH -	Adrenocorticotropic hormone
AGRF -	Australian Genome Research Facility
bp -	Base pair
cDNA -	Complementary DNA
CRH -	Corticotropin Releasing Hormone
CRH-BP -	CRH binding protein
CRH-R -	CRH receptor
cAMP -	cyclic AMP
DISC -	Death Inducing Signalling Complex
DAF -	Decay Accelerating Factor
DTH -	Delayed type hypersensitivity
dH ₂ O -	Distilled water
ERV -	Endogenous retroviral/retrovirus
ERVs -	Endogenous retroviruses
env gene -	Envelope gene
ERK -	Extracellular signal-regulated kinase
EVT -	Extra villous trophoblast
FADD -	Fas-associated death domain
FasL -	Fas Ligand
FPLC -	Fast Protein Liquid Chromatography

FeLV -	Feline Leukaemia Virus
Gcma -	Glial cells missing a
GM-CSF -	Granulocyte macrophage colony stimulating factor
HBSS -	Hanks buffered salt solution
HPLC –	High Performance Liquid Chromatography
Hitrap IMAC -	Hitrap Immobilised Metal Affinity Chromatography
HRP -	Horse radish peroxidase
HERV -	Human Endogenous Retrovirus
HERVs -	Human Endogenous Retroviruses
HIV -	Human Immunodeficiency Virus
HLA -	Human Leukocyte Antigen
Ig -	Immunoglobulin
ISD -	Immunosuppressive domain
IDO -	Indoleamine 2,3,-dioxygenase
IFN -	Interferon
IL -	Interleukin
JAK3 -	Janus Kinase 3
IPTG -	Isopropyl β -D-1-thiogalactopyranoside
LDH -	Lactate Dehydrogenase
LAL -	Limulus Amebocyte Lysate
LPS -	Lipopolysaccharide
LCMS -	Liquid Chromatography mass spectrometry
LB –	Luria broth

MHC -	Major Histocompatibility Complex
MPMV -	Mason Phizer Monkey Virus \
MAC -	Membrane Attack Complex
MCP -	Membrane Co-factor Protein
mRNA -	Messenger RNA
μg -	Microgram
μM -	Micromolar
mg -	Milligram
mM -	Millimolar
MEK –	mitogen-activated protein kinase/ERK kinase
M -	Molar
MMuLV -	Moloney Murine Leukaemia Virus
ng -	Nanogram
nm -	Nanometres
nM -	Nanomolar
NK cells -	Natural Killer cells
OD -	Optical density
1D -	One dimensional
PBMC -	Peripheral Blood Mononuclear Cells
PMA -	phorbol 12-myristate 13-acetate
PBS -	Phosphate buffered saline
Pi3-K -	phosphoinositide-3 kinase
PHA -	Phytohaemagglutinin

PCR -	Polymerase Chain Reaction
PIBF -	progesterone induced blocking factor
PD1 -	Programmed Death 1
PDL1 or PDL2 -	Programmed death Ligand 1 / 2
PKA -	Protein kinase A
RT-PCR -	Real-time Polymerase Chain Reaction
RCA -	Regulators of Complement Activation
T-reg cells -	Regulatory T cells
rpm -	Revolutions per minute
RT -	Room temperature
SDS-PAGE -	Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis
ASCT2 -	Solute Carrier Family 1 (neutral amino acid transporter),
member 5	
SEB -	Staphylococcal Enterotoxin B
SOB -	Super Optimal Broth
SOCS -	Suppressors of cytokine signaling
TB -	Transformation buffer
TGF -	Transforming Growth Factor
TAE buffer -	Tris-acetate-EDTA buffer
TBST -	Tris-buffered saline Tween 20
TE buffer -	Tris-EDTA buffer
TNF -	Tumour Necrosis Factor
2D -	Two dimensional

2D buffer -	Two dimensional electrophoresis lysis buffer
Th1 -	Type 1 helper T cells
Th2 -	Type 2 helper T cells
UV -	Ultra-violet